GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akers Biosciences Inc (NAS:AKER) » Definitions » Retained Earnings

Akers Biosciences (Akers Biosciences) Retained Earnings : $-137.16 Mil (As of Dec. 2020)


View and export this data going back to 2014. Start your Free Trial

What is Akers Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Akers Biosciences's retained earnings for the quarter that ended in Dec. 2020 was $-137.16 Mil.

Akers Biosciences's quarterly retained earnings declined from Jun. 2020 ($-126.75 Mil) to Sep. 2020 ($-133.88 Mil) and declined from Sep. 2020 ($-133.88 Mil) to Dec. 2020 ($-137.16 Mil).

Akers Biosciences's annual retained earnings declined from Dec. 2018 ($-115.70 Mil) to Dec. 2019 ($-119.58 Mil) and declined from Dec. 2019 ($-119.58 Mil) to Dec. 2020 ($-137.16 Mil).


Akers Biosciences Retained Earnings Historical Data

The historical data trend for Akers Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akers Biosciences Retained Earnings Chart

Akers Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -97.48 -104.85 -115.70 -119.58 -137.16

Akers Biosciences Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119.58 -123.12 -126.75 -133.88 -137.16

Akers Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Akers Biosciences  (NAS:AKER) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Akers Biosciences (Akers Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
Executives
Billy Joe White director 191 OTTO ST., PORT TOWNSEND WA 98368
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Christopher C Schreiber director, officer: Exec. Chairman and President AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
John J Gormally director, officer: Chief Executive Officer 80 WALSH DRIVE, MAHWAH NJ 07430
Gary M Rauch officer: VP - Finance, Treasurer 842 ST REGIS COURT, WEST DEPTFORD NJ 08051
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Brandon Thomas Knox director 771 EAGLE ROAD, VILLANOVA PA 19085
Akers Raymond Francis Jr director, officer: Executive Chairman, Secretary 171 E. ESSEX AVE, SEWELL NJ 08080
Thomas J Knox director 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103
Robert E Andrews director 215 4TH AVENUE, HADDON HEIGHTS NJ 08035